Loading...
XNASDMAC
Market cap224mUSD
Dec 24, Last price  
5.26USD
1D
-2.14%
1Q
27.05%
Jan 2017
139.09%
IPO
130.70%
Name

DiaMedica Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:DMAC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.28%
Rev. gr., 5y
%
Revenues
0k
33,88125,67925,737160,6230000000000500,00000000
Net income
-19m
L+41.72%
000000000000-2,223,144-4,260,000-5,734,000-10,649,000-12,292,000-13,592,000-13,676,000-19,381,000
CFO
-19m
L+62.70%
000000000000-3,023,179-3,900,000-5,696,000-9,102,000-9,185,000-12,252,000-11,511,000-18,728,000
Earnings
Mar 17, 2025

Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
URL
https://www.diamedica.com/
IPO date
Jan 04, 2008
Employees
16
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
21,297
14,026
13,670
Unusual Expense (Income)
NOPBT
(21,297)
(14,026)
(13,670)
NOPBT Margin
Operating Taxes
43
28
28
Tax Rate
NOPAT
(21,340)
(14,054)
(13,698)
Net income
(19,381)
41.72%
(13,676)
0.62%
(13,592)
10.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
36,848
30,093
BB yield
-39.84%
-38.84%
Debt
Debt current
166
69
49
Long-term debt
717
869
55
Deferred revenue
Other long-term liabilities
Net debt
(52,012)
(32,564)
(45,008)
Cash flow
Cash from operating activities
(18,728)
(11,511)
(12,252)
CAPEX
(24)
(81)
(22)
Cash from investing activities
(18,299)
11,538
(20,537)
Cash from financing activities
36,842
(6)
30
FCF
(21,265)
(14,502)
(13,636)
Balance
Cash
52,895
33,502
45,112
Long term investments
Excess cash
52,895
33,502
45,112
Stockholders' equity
(115,552)
(96,251)
(82,552)
Invested Capital
167,092
128,547
126,628
ROIC
ROCE
EV
Common stock shares outstanding
32,567
26,443
20,773
Price
2.84
79.74%
1.58
-57.64%
3.73
-63.21%
Market cap
92,489
121.36%
41,783
-46.08%
77,485
-51.27%
EV
40,477
9,219
32,477
EBITDA
(21,267)
(14,001)
(13,646)
EV/EBITDA
Interest
353
Interest/NOPBT